MBX Biosciences, Inc. SEC filings MBX
MBX Biosciences, Inc. has 232 filings in SEC EDGAR's recent list, going back to May 10, 2019. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 8, 2026 | — |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEF 14A | Proxy statement | Apr 22, 2026 | Apr 22, 2026 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Apr 22, 2025 |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carmel, IN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1776111
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.